Abstract Background No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. Methods In this multi‐institutional retrospective study, […]
Abstract Background No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. Methods In this multi‐institutional retrospective study, […]
Abstract Background No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. Methods In this multi‐institutional retrospective study, […]
Abstract Background No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. Methods In this multi‐institutional retrospective study, […]
Abstract Background No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. Methods In this multi‐institutional retrospective study, […]
Objective To compare the outcomes for laparoscopic vascular hitch (VH) and dismembered pyeloplasty in patients with pelvi‐ureteric junction obstruction (PUJO) secondary to crossing vessels (CV). Patients and Methods Patients who underwent laparoscopic management of CV at our institution were identified between 2008 and 2020. Baseline characteristics and outcome measures were compared between those who underwent […]
Objective To compare the outcomes for laparoscopic vascular hitch (VH) and dismembered pyeloplasty in patients with pelvi‐ureteric junction obstruction (PUJO) secondary to crossing vessels (CV). Patients and Methods Patients who underwent laparoscopic management of CV at our institution were identified between 2008 and 2020. Baseline characteristics and outcome measures were compared between those who underwent […]
Objectives To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and Methods We performed a retrospective cohort study collecting clinicopathological, treatment, and outcome data for patients with aUC receiving ICIs from 2013 to 2020 across 24 […]
Objectives To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and Methods We performed a retrospective cohort study collecting clinicopathological, treatment, and outcome data for patients with aUC receiving ICIs from 2013 to 2020 across 24 […]
Objectives To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and Methods We performed a retrospective cohort study collecting clinicopathological, treatment, and outcome data for patients with aUC receiving ICIs from 2013 to 2020 across 24 […]